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OBJECTIVE—To establish a method for isolation and culture
of subcutaneous microvascular endothelial cells (MVEC) from
small human tissue biopsies to compare gene and protein ex-
pression of insulin signaling molecules in MVEC from insulin-
resistant and healthy control subjects.
RESEARCH DESIGN AND METHODS—Stromavascular cells
from subcutaneous needle biopsies of type 2 diabetic and control
subjects were expanded in culture and the endothelial cells
selected with magnetic immune separation. Western blots and
RT-PCR were used for protein and gene expression assays.
RESULTS—At least 99% of the expanded primary MVEC could
be characterized as endothelial cells. The expression of insulin
receptors was low, but insulin increased tyrosine phosphoryla-
tion of both the insulin receptor and insulin receptor substrate
(IRS)-1 and activated protein kinase B (PKB). The IRS-1 protein
expression was reduced and the serine phosphorylation of PKB
in response to insulin attenuated whereas basal and insulin-
stimulated phosphorylation of extracellular signal–related kinase
(ERK)1/2 was increased in type 2 diabetes MVEC. Endothelin
(ET)-1 mRNA levels were signiﬁcantly higher in type 2 diabetes
cells. The addition of ET-1 increased the phosphorylation of
mitogen-activated protein kinase (MAPK), an effect antagonized
by the MEK-1 inhibitor PD98059. Furthermore, the endothelin
ETA and ETB receptor antagonists BQ123 and BQ788 decreased
basal MAPK activity in type 2 diabetes MVEC and prevented the
ET-1–induced activation.
CONCLUSIONS—We developed a system for isolation and
culture of human MVEC from small needle biopsies. Our obser-
vations support the concept of “selective” insulin resistance,
involving IRS-1 and the PI3kinase pathway, as an underlying
factor for a dysregulated microvascular endothelium in type 2
diabetes. Our data also support a role of ET-1 for the increased
MAPK activity seen in nonstimulated type 2 diabetes MVEC.
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ethods to culture human vascular endothe-
lium have been available for several decades
(1–3). Adipose tissue is a suitable source of
endothelial cells because of its rich network
of capillaries (4). Subcutaneous fat is relatively easy to
access during elective surgery or liposuction; hence, strat-
egies have been outlined to create an antithrombogenic
cell lining in vascular prosthetic devices (5,6). However,
aspiration of subcutaneous fat has never been used as a
source of microvascular endothelial cells (MVEC) in met-
abolic research because overgrowth of ﬁbroblasts and
other stromal cells has been a substantial problem. A key
aim of the present study was to improve the isolation and
expansion procedures of human MVEC to enable molecu-
lar studies, including insulin signaling and effects, in
endothelial cells from subcutaneous needle biopsies ob-
tained from subjects with different clinical phenotypes.
Accordingly, we have further developed available methods
(7–11) for immunoselection and subsequent culture of
MVEC to obtain, validate, and characterize endothelial
cells from small human tissue specimens.
We have previously shown that insulin resistance and
type 2 diabetes are associated with an impaired insulin
signaling because of a reduced expression of the key
docking protein insulin receptor substrate (IRS)-1 in hu-
man subcutaneous adipose tissue (12), and this is also
associated with different aspects of the insulin resistance
syndrome including surrogate markers of atherosclerosis
(13). An impaired IRS-1 activation by insulin in macrovas-
cular endothelial cells because of a point mutation is
associated with endothelial dysfunction (14).
Endothelins are a family of vasoactive peptides (ET-1,
ET-2, and ET-3) that signal through the two G-coupled
protein receptors ETA and ETB. Endothelin (ET)-1 is
secreted by endothelial cells and produces multiple ac-
tions like regulation of vascular tone, tissue remodeling,
induction of proliferation, chemotaxis of macrophages,
activation of smooth muscle cells, and differentiation of
ﬁbroblasts (15). Elevated ET-1 plasma levels have also
been reported in insulin-resistant states like type 2 diabe-
tes and obesity (16,17).
Endothelial dysfunction is a known facet in patients
with insulin resistance (18), and ET-1 is considered to play
a role for this by interfering with the insulin-signaling
pathway in the arterial wall (19).
We provide detailed information on how to isolate and
propagate MVEC from needle biopsies of the subcutane-
ous adipose tissue. We also characterized insulin signaling
and provide evidence that ET-1 is overexpressed in MVEC
from type 2 diabetes donors, leading to increased mitogen-
activated protein kinase (MAPK) activity.
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Source of adipose tissue and MVEC. Human needle biopsies of the
subcutaneous adipose tissue were obtained from the abdominal region of
nondiabetic (n  12) and type 2 diabetic (n  12) subjects under local
anesthesia (Xylocain 10 mg/ml) (Astra Zeneca AB, So ¨derta ¨lje, Sweden), as
previously described (12). All subjects were recruited via an advertisement in
a local newspaper, and their clinical characteristics are shown in Table A1
(available in the online appendix at http://diabetes.diabetesjournals.org/
content/early/2009/06/23/db08-0961/suppl/DC1).
About3go ftissue was incubated in sterile Medium199 (Invitrogen,
Paisley, U.K.) containing 25 mmol/l HEPES, 4% BSA, 5.5 mmol/l glucose, and
0.8 mg/ml collagenase in a shaking water bath at 37°C. After 30–50 min, the
digest was ﬁltered through a sterile nylon mesh (pore size 250 m) and
washed four times with fresh medium as described before (20). Two fractions
were obtained: the upper fraction containing the ﬂoating isolated adipose cells
and the lower fraction containing the stromavascular cells.
The lower fraction was collected into 50-ml Falcon tubes, and, after
centrifugation (1,300 rpm for 5 min), the pellet was resuspended in endothelial
cell growth medium Bulletkit (EGM-2-MV) consisting of endothelial cell basal
medium-2 (EBM-2) supplemented with EGM-2-MV SingleQuots containing
hEGF, hydrocortisone, FBS, vascular endothelial growth factor, R3-IGF-1,
ascorbic acid, and gentamicin sulfate/amphotericin-B (GA-1000) (Clonetics,
BioWhittaker, Verviers, Belgium). FGFb was not added to the medium.
The cells obtained were seeded into a 75 cm
2 culture ﬂask and allowed to
grow at 37°C and 5% CO2 in the same media. Before the cells reached
conﬂuence, after approximately 1 week, the heterogeneous pool of cells was
exposed to a CD31-positive selection as described below. The isolated
adipocytes in the ﬂoating fraction were washed four times in fresh Medium
199, resuspended at 2% cytocrit, and used as described below. All subjects
gave their written informed consent, and the study was approved by the Ethics
Committee of the University of Gothenburg.
Endothelial cell isolation and culture. The human MVEC selection was
performed with the Dynabeads magnetic CD31 MicroBeads cell sorting
system (Invitrogen).
The heterogeneous cell population, containing the adipose tissue–derived
stromavascular cells, was washed twice with PBS and incubated on a rocking
platform (25 revolution/min) during 15 min with 4 ml of PBS/0.2% BSA
containing 100 l of Dynabeads (2.8  10
5 beads/ml) coated with CD31
antibody (PECAM-1). The beads rapidly target and partially coat the endothe-
lial cells expressing the CD31 receptor.
After the incubation, the culture was washed twice with PBS and
trypsinized. The cells were collected into a tube and centrifuged for 3 min at
1,300 rpm. The pellet was resuspended in PBS/0.2% BSA, collected intoa2m l
microcentrifuge tube, and placed in a magnet (Dynal MPC-S) (Invitrogen),
following the manufacturer’s recommended protocol for washings and ﬁnal
extraction. The CD31-negative cells (with no beads attached) were removed
during the successive washings.
The positive selected endothelial cells were resuspended in endothelial cell
growth medium Bulletkit (EGM-MV2) and maintained at 37°C and 5% CO2. The
cells obtained with this procedure were 99% endothelial cells with typical
cobblestone morphology. The endothelial cells were characterized by indirect
immunoﬂuorescense and acetylated LDL uptake. The cells were used before
passage seven.
Immunocytochemistry of MVEC. For immunoﬂuorescence, the cells were
incubated in eight-well plastic chamber slides (Nunc, A/S, Roskilde, DK) for
48 h. The cells were washed twice with PBS and ﬁxed for 10 min in methanol.
After three rinses in PBS, the cells were incubated with the human primary
antibody against von Willebrand Factor (vWF) (DAKO A082) (1:50 dilution in
PBS/3% BSA) for 1 h. The culture was washed three times with PBS and
incubated with the ﬂuorescein isothiocyanate–labeled secondary antibody
(DAKO F0205) (1:50 dilution in PBS/3% BSA) for 1 h and washed again.
Acetylated LDL uptake of MVEC. The cells were incubated in eight-well
plastic chamber slides for 48 h. Acetylated LDL labeled with 1,1-dioctadecyl-
3,3,3,3-tetramethylindo-carbocyanine perchlorate (Dil-Ac-LDL) (Biomedical
Technologies) was added to the culture medium at a ﬁnal concentration of 10
g/ml, and the cells were incubated at 37°C for 4 h. The cells were ﬁxed for
30 min in 3% formaldehyde solution, mounted, and observed by ﬂuorescence
microscopy.
Tube formation. Rat-tail collagen type I, 10 mg/ml (BD Biosciences, Stock-
holm, Sweden), was neutralized by the addition of 1N NaOH, H2O, and PBS
following the manufacturers recommendations. The mix was poured into
12-well culture plates (200 l/well) and allowed to solidify for1hi na
humidiﬁed atmosphere of 5% CO2 at 37°C. After solidiﬁcation, the gels were
preincubated with growth medium 30 min before the cells were seeded. The
tube formation was monitored by phase-contrast microscopy.
Protein extraction of endothelial cells. The cultured cells were thoroughly
washed with PBS, deprived of serum and EGM-2-MV SingleQuots additions for
4 h, before adding insulin for 20 min. ET-1, BQ123, BQ788 (Sigma-Aldrich,
Stockholm, Sweden), or PD98059 (Calbiochem-Merck Chemicals, Notting-
ham, U.K.) were added to the culture media for 24 h at the indicated
concentrations. When used in combination with other factors, PD98059 was
added 1 h before.
The cells were washed with PBS and then lysed in lysis buffer on ice (21).
The lysate was vortexed and rocked for2ha t4 ° Ca n dt h eproteins quantiﬁed
by the bicinchonic acid method (Pierce, Rockford, IL).
Preparation of adipose cells: protein and RNA extraction. The isolated
human adipocytes, as described above, were distributed into plastic vials
(12–15% cell suspension) and incubated with 100 nmol/l insulin for 15 min. The
cells were rapidly separated by centrifugation through silicone oil and
suspended in lysis buffer. The lysate was vortexed and rocked for2ha t4 ° C
as previously reported (21). The proteins were quantiﬁed by the bicinchonic
acid method. RNA was extracted according to Chirgwin et al. (22).
RNA extraction of endothelial cells. The cultured cells were deprived of
serum and EGM-2 MV SingleQuots additions and insulin was added, when
speciﬁed, for 24 h. Total cellular RNA was extracted with RNeasy (Quiagen
Gmbh, Hilden, Germany). The mRNA expression was analyzed with the ABI
PRISM 7900 sequence detection system (TaqMan, Applied Biosystems, Foster
City, CA) using18s rRNA as endogenous control subjects (23). The gene
expression predesigned primer and probe set #Hs00167166_ml was used for
eNOS and #Hs00174961_m1 for ET-1 gene analysis (Applied Biosystems).
Human umbilical vein endothelial cells. Human umbilical vein endothelial
cells (HUVECs) (ATCC-CRL-1730) were grown in Kaighn’s modiﬁed F12K
media (American Type Culture Collection [ATCC]) from LGC Promochem
(Boras, Sweden). The media was supplemented with 0.1 mg/ml heparin and
0.03 mg/ml endothelial cell growth supplement, both from Sigma-Aldrich, and
10% FBS (GIBCO, Invitrogen).
Immunoblotting. Crude cell extracts were boiled in Laemmli buffer contain-
ing 150 mmol/l dithiothreitol for 5 min. The samples were analyzed by
SDS-PAGE (7.5 or 10%). Proteins were transferred from the gel to nitrocellu-
lose sheets, blocked in 5% fat-free milk, and probed with the different primary
antibodies according to the manufacturer’s recommendations. IRS-1 and
MAPK antibodies were from Upstate Biotechnology (Millipore, Solna, Swe-
den), p-PKB, PKB, and p-MAPK were from Cell Signaling (New England
Biolabs, Hertfordshire, U.K.), insulin receptor and eNOS were from Transduc-
tion (BD Biosciences, Erembodegem, Belgium), and antiphosphotyrosine
(pY99) was from Santa Cruz Biotechnology (SDS, Falkenberg, Sweden). The
proteins were detected by enhanced chemiluminescence using horseradish
peroxidase–labeled secondary antibodies (Amersham Biosciences, Bucking-
hamshire, U.K.), and the intensity of the bands was quantitated with a laser
densitometer (Molecular Dynamics, Sunnyvale, CA).
Immunoprecipitations. Cell lysates (60 g) were immunoprecipitated with
anti-insulin receptor antibody according to the recommendation of the
manufacturers. Subsequently, the immune complexes were precipitated with
Protein A/G Plus-Agarose (Santa Cruz Biotechnology) for 90 min at 4°C. The
immunoprecipitates were washed three times with lysis buffer. The samples
were analyzed by SDS-PAGE (7.5%) and immunoblotted as described above.
cGMP measurements. Cellular cGMP was measured by the cGMP Enzyme-
immunoassay Biotrak System (Amersham Biosciences) following the manu-
facturer’s recommendations.
Statistical analysis. Data analyses are presented as means  SE. Student’s
t test was used to test for statistical signiﬁcance.
RESULTS
Cell recovery of the CD31 isolation method. At least
99% of the primary MVEC generated by the CD31 extrac-
tion showed a positive staining for vWF and LDL uptake.
However, there was a certain variation between the sub-
jects regarding the number of nonendothelial cells (CD31
negative) that were recovered with the positive cells. This
variation was not related to the subject phenotype (control
or type 2 subjects) nor to the deﬁned experimental condi-
tions used. The nonendothelial cells were easy to distin-
guish from the MVEC in culture and were easily removed
by performing a new CD31 extraction in a subsequent
passage.
MVEC proliferation was slow and sensitive to seed-
ing densities. A suitable density of cells was around 3  10
3
cells/cm
2. The adherent cultured human MVEC monolayer
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maintained throughout the 10–13 passages studied (Fig.
1A). Later passages were associated with reduced growth
and distorted cell borders. The cells never formed thick
aggregates and maintained their contact inhibition.
von Willebrand Factor and Ac-LDL. The MVEC were
positive for the endothelial-speciﬁc vWF immunostaining
(Fig. 1B). In addition, the cells incorporated acetylated
LDL, another marker characterizing endothelial cells (Fig.
1C).
Endothelial cell tube formation. The ability to form a
capillary/tube-like network is a specialized function of
vascular endothelial cells. We characterized the subcuta-
neous MVEC by their ability to form capillary-like struc-
tures. Figure 1D shows the morphogenic response of
MVEC in collagen and EGM-MV2 media. Morphologic
changes and reorganization of the cells were apparent as
early as 12 h after initiation of the culture.
Insulin signaling pathway and MAPK activation. We
investigated the responsiveness to insulin of the adipose
tissue–derived MVEC from healthy and type 2 diabetes
individuals. For comparison, we performed parallel exper-
iments with the HUVEC line, a well-documented endothe-
lial cell line.
Expression of the insulin receptor was low in MVEC
compared with HUVEC, but there was a clear insulin-
stimulated tyrosine phosphorylation of the receptor in
both type 2 and control subjects in MVEC and in HUVECs
(Fig. 2).
Because the presence of insulin receptor in MVEC is a
controversial issue, we wanted to further validate the
presence of insulin receptors by immunoprecipitating the
insulin receptors and immunoblotting for both phosphoty-
rosine and receptor protein. As shown (Fig. 2, right
panel), insulin receptors are indeed present in MVEC
albeit at a low level.
Both main docking proteins for insulin, IRS-1 and IRS-2,
were expressed as well as the downstream signaling
proteins PKB/Akt and the MAPKs extracellular signal–
related kinase (ERK)1/2. IRS-1 was clearly the predomi-
A
C D
B
FIG. 1. A–D: Characterization of human subcutaneous microvascular endothelial cells (MVEC) in culture. A: Conﬂuent MVEC viewed under
phase-contrast microscopy exhibit the typical endothelial cobblestone morphology. B: Fluorescence microscopy showing positive immunoreac-
tivity for vWF and (C) for Ac LDL uptake. D: Phase-contrast micrograph showing tube formation by MVEC grown on collagen. Original
magniﬁcation A and D  40; B and C  100. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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FIG. 2. Left panel: Insulin receptor expression and activation by insulin. MVEC from control and type 2 diabetic subjects as well as HUVEC cells
were starved for 4 h and incubated in serum free media for 20 min with or without insulin (100 nmol/l). The lysates were subjected to
immmunoprecipitation with an anti-IR antibody and the immunoprecipitated proteins were separated on a 7.5% SDS-PAGE, transferred and
probed with antiphosphotyrosine (pY99). The ﬁgure shows representative immunoblots. Right panel: The insulin receptors were immunopre-
cipitated and immunoblotted with antiphosphotyrosine (pY99) and anti-insulin receptor antibodies. bas, basal; ins, insulin.
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(data not shown).
Similar to our previous observations in human adipo-
cytes (12), IRS-1 protein expression was markedly de-
creased in MVEC from type 2 diabetic subjects (Fig. 3).
This reduction was also reﬂected by the impaired acti-
vation and serine phosphorylation of the downstream
protein, protein kinase B (PKB)/Akt, in MVEC from type 2
diabetic subjects, whereas PKB/Akt protein expression
was unchanged (Fig. 4, upper panel). This observation
was conﬁrmed in four separate immunoblots quantiﬁed by
scanning and shown in Fig. 4 (bottom panel). A pro-
nounced insulin-stimulated activation of PKB was also
seen in the HUVEC cells (Fig. 4, upper panel).
The MAPKs ERK1/2 had an increased phosphorylation
in the basal state in MVEC from type 2 diabetic subjects
(Fig. 5, upper panel). Insulin further increased the MAPK
phosphorylation in control subject MVECs (P  0.057)
while there was no effect of insulin (P  0.18) in the type
2 diabetic subject cells, probably masked by the high basal
MAPK/ERK activation. This observation was conﬁrmed in
ﬁve separate experiments measuring the p-MAPK/MAPK
volume ratios (Fig. 5, bottom panel), supporting that the
major change was because of an increased phosphoryla-
tion of the MAPK in the basal state.
Effects of insulin on eNOS activation. Surprisingly,
there was also a very low protein expression of eNOS in
the MVEC and, as expected, in the isolated adipose cells
from the same individuals compared with HUVEC (Fig. 6,
top). The gene expression of eNOS was also almost
undetectable in the MVEC, from both control and type 2
diabetic subjects, while there was a clear expression of
both the gene and protein in HUVECs (Fig. 6, bottom
panel). Insulin had no effect on the expression of eNOS
mRNA in MVEC while the levels were signiﬁcantly in-
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FIG. 5. Upper panel: MVEC from different control (n  5) and type 2
diabetic (n  5) subjects were starved for 4 h and incubated for 20 min
with or without insulin (100 nmol/l). The lysates were separated on a 10%
SDS-PAGE, transferred, and probed with phosphospeciﬁc tyrosine/threo-
nine MAPK (ERK1 and ERK2) or MAPK antibodies. Bottom panel: The
graph shows the p-MAPK/MAPK volume ratio. The results are means SE
of scanned data from ﬁve separate experiments *P  0.02, **P  0.01
compared with respective control subjects. bas, basal, (); ins, insulin, (f).
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FIG. 3. MVEC from control and type 2 diabetic subjects were starved
for 4 h and incubated for 20 min with or without insulin (100 nmol/l).
The lysates were separated on SDS-PAGE, transferred, and analyzed
by immunoblotting. The upper panel shows representative blots of the
IRS-1 protein. The bands on top correspond to a long 10% gel and the
bands under to a short 7.5% gel. These gels were loaded with different
amounts of protein. The bars in the graph below represent the means
of scanned data from three control and three type 2 subjects *P  0.05
and ***P < 0.001 compared with respective control subjects. bas, basal,
(); ins, insulin, (f).
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FIG. 4. MVEC from different control (n  4) and type 2 diabetic (n  4)
subjects as well as HUVEC cells were starved for 4 h and incubated for 20
min with or without insulin (100 nmol/l). The lysates were separated on a
10% SDS-PAGE and analyzed by immunoblotting with antiphosphoserine
(p-ser) PKB/Akt or anti-PKB/Akt antibodies. Bottom panel: The graph
shows the p-ser PKB/PKB volume ratio from four separate experiments
quantiﬁed by scanning; *P  0.04 compared with control subjects. bas,
basal; ins, insulin, (f).
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to activate eNOS, we incubated the cells with or without
the hormone for 1, 3, 5, 15, or 20 min and measured
phosphorylation of Ser
1177 and Thr
495. Because no activa-
tion was found, we investigated the effect of insulin on
cyclic GMP formation. However, insulin did not increase
cyclic GMP levels in human cultured MVEC from subcu-
taneous adipose tissue (data not shown). Thus, we con-
clude that eNOS is not an important target for insulin in
these cells, at least under the culture conditions used.
ET-1 expression. As shown in Fig. 7, ET-1 mRNA levels
were signiﬁcantly higher in cells from type 2 diabetes individuals, both when compared with cells from the
control group as well as with HUVECs, while there was no
signiﬁcant difference between the control group and
HUVECs. Adding insulin (100 nmol/l) for 24 h did not
increase ET-1 expression in any of the three groups
studied (Fig. 7).
To further explore its role, we added ET-1 (100 nmol/l)
to the culture medium and found that it increased ERK1/2
phosphorylation in control subject MVEC (Fig. 8, upper
panel).
The addition of the ETA (BQ123) and ETB (BQ788)
receptor antagonists (20 mol/l) as well as the MEK-1
inhibitor PD98059 (50 mol/l) prevented this effect of ET-1
(Fig. 8, upper panel). It should be noted that both ET-1
receptor antagonists were required because both A and B
receptors were present in MVEC (data not shown).
To examine if the increased MAPK activation in the
nonstimulated state in MVEC from type 2 diabetes indi-
viduals was because of the increased endothelin, we
incubated the cells with both ETA and ETB receptor
antagonists. As shown in Fig. 8 (middle and bottom
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lysates separated on a 10% SDS-PAGE, transferred and probed with
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nmol/l) for 24 h. The RNA was extracted as described in RESEARCH
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FIG. 7. ET-1 gene expression. MVEC from different control (n  8) and
type 2 diabetic (n  8) subjects as well as HUVEC cells were starved
and incubated with or without insulin (100 nmol/l) for 24 h. The RNA
was extracted as described in RESEARCH DESIGN AND METHODS and the
ET-1 gene expression quantiﬁed by TaqMan RT-PCR. The results,
expressed as mRNA/18s rRNA ratio, are the means of data from eight
(MVEC) or ﬁve (HUVEC) experiments. *P < 0.05 compared with
respective control subjects, #P < 0.05 compared to type 2 MVEC. Basal
(); insulin (f).
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FIG. 8. MVEC were starved for 4 h and incubated as shown with ET-1
(100 nmol/l), PD98059 (50 mol/l), or the ET-1 receptor antangonists
BQ123 and BQ788 (20 mol/l) for 24 h. The cell lysates from control
(upper panel) and type 2 diabetic subjects (middle panel) were
separated on a 10% SDS-PAGE, transferred and probed for phos-
phospeciﬁc tyrosine/threonine MAPK (ERK1 and ERK2) and reprobed
with MAPK protein. The ﬁgure shows representative immunoblots. The
bottom graph shows the p-MAPK/MAPK volume ratio as means  SE of
scanned data from four separate experiments, *P < 0.05 compared with
basal. bas, basal; PD, PD98059.
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type 2 diabetic subjects was normalized by the ET-1
receptor antagonists. This was also seen with the MEK-1
inhibitor PD98059. Taken together, our results show that
ET-1 is increased in MVEC from type 2 diabetes individu-
als and that this activation can account for the increased
MAPK activation seen in the basal state.
DISCUSSION
This study describes an improved method for the primary
culture of an apparently pure population of MVEC ob-
tained from a subcutaneous needle biopsy (around 3 g),
using CD31 extraction. In general, the puriﬁcation steps
had to be performed at least twice to obtain a pure cell
population. The cells displayed the typical cobblestone
morphology, positive immunostaining for the vWF, uptake
of acetylated LDL, as well as capacity to form a capillary/
tube-like network on a collagen gel. The usefulness of our
procedure is illustrated by the fact that the MVEC can be
expanded and used to characterize gene expression and
hormone signaling. This opens up new possibilities to
study molecular mechanisms in MVEC in relation to the
clinical phenotype including endothelial dysfunction.
We focused on characterizing insulin signaling and
action in the MVEC because these cells are considered to
be important target cells for insulin. We have previously
shown that IRS-1 protein expression, like GLUT4, is re-
duced in the adipose cells in insulin resistance and is,
indeed, a biomarker of the IRS (12). Moreover, a group of
subjects exhibiting low adipocyte IRS-1 expression dis-
played early signs of atherosclerosis, including an in-
creased intima-media thickness (13) and an increased
vascular stiffness as measured with pulse tonometry (24)
compared with subjects with “normal” adipocyte IRS-1
expression. Animal studies have also shown that in the
vasculature of obese Zucker rats, insulin resistance affects
the PI3Kinase pathway but not other pathways of insulin
signaling including the MAPK pathway (25). This “selec-
tive” insulin resistance would provide insights into the
mechanisms for the increased shedding of cellular adhe-
sion molecules in insulin-resistant subjects (26), the en-
hanced vasoconstrictory effect of insulin (27), and the
pathophysiology of microvascular complications in diabe-
tes (28).
The MVEC showed a low, but similar, expression of the
insulin receptor and its tyrosine phosphorylated form in
type 2 diabetic patients and control subjects, whereas
IRS-1 protein expression and phosphorylation by insulin
were markedly attenuated in type 2 diabetic patients.
Consequently, serine phosphorylation of PKB/Akt was
impaired in agreement with an impaired signaling through
the PI3Kinase pathway. However, we were unable to
observe any difference in eNOS expression and phosphor-
ylation in response to insulin between the groups because
of a very low expression of eNOS in the MVEC. This was
unexpected but low eNOS expression in MVEC has been
reported before by some (29) but not all studies with
MVEC (11). However, our ﬁndings were corroborated by
measuring cGMP production that also was extremely low.
An intriguing ﬁnding was the increased nonstimulated
(basal) as well as insulin-stimulated phosphorylation of
ERK1/2 in cells from diabetic subjects. This observation
ﬁts with the known imbalance of insulin action in the
microvasculature often referred to as pathway-selective
insulin resistance in obesity and diabetes (25,26,30).
The increased phosphorylation of ERK1/2 in diabetes
may be an important reason for the decreased IRS-1
protein expression since MAPK phosphorylate IRS-1 on
serine residues leading to an increased degradation of the
protein (31). Interestingly, basal ERK1/2 phosphorylation
is also increased in adipose cells in type 2 diabetes (32),
and IRS-1 protein is also decreased (33). The ﬁnding of an
increased ERK1/2 phsophorylation together with de-
creased IRS-1 in MVEC cultured for up to seven passages
in vitro suggests a genetic cause and/or that the MVEC
release factors that activate the cells.
DNA methylation and posttranslational histone modiﬁ-
cations are epigenetic mechanisms that are known to
inﬂuence mammalian gene expression. Type 2 diabetes
shows a progressive development with increasing age and
environmental sensitivity. These characteristics make this
disease suitable for epigenetic changes, but it is only
recently that we have started to understand the role of
these epigenetic mechanisms. Therefore, it is possible that
epigenetic mechanisms, because of high glucose concen-
trations or other factors (34,35), may lead to a long-term
activation of genes in the type 2 diabetes MVEC. However,
further studies are needed to address this point.
Interestingly, ET-1 expression was signiﬁcantly in-
creased in the MVEC from diabetic subjects when com-
pared with both nondiabetic subjects and HUVECs. In fact,
there was no difference between the nondiabetic and
HUVECs, further corroborating the increase in the dia-
betic cells. Increased circulating ET-1 levels have also
been reported in type 2 diabetes (36,37), and this ﬁnding is
consistent with the increased ERK1/2 activation seen since
these kinases have been associated with an increased
endothelin expression (30).
In our study, the increased ET-1 expression was not
altered by the presence of insulin and, thus, is more likely
a consequence of other activators. The nature of these
upstream factors is a current focus of research.
Addition of ET-1 to the culture media increased MAPK
phosphorylation in control subject MVEC. This effect was
prevented by PD98059 showing that ERK1/2 is a target for
ET-1 in MVEC. Importantly, the increased nonstimulated
(basal) MAPK activation in MVEC from type 2 diabetic
subjects was completely antagonized by the addition of
the ET-1 receptor antagonists BQ123 and BQ788. The use
of both antagonists was required because MVEC were
found to express both the ETA and ETB receptors. These
results support the concept that the increased ET-1 ex-
pression plays a major role for the increased basal MAPK
activation seen in MVEC of type 2 diabetic subjects.
ET-1 was recently shown to impair insulin signaling in
adipose cells by decreasing the tyrosine phosphorylation
and expression of IRS-1 (37,38). Thus, it is also possible
that the reduced IRS-1 protein in adipose cells from type 2
diabetic subjects is because of the increased ET-1 and
MAPK activation as discussed above. If this is indeed the
case, it would imply that the endothelial cells can directly
cross talk with the adipose cells and modulate their insulin
sensitivity and action. It should also be added that only
ERK1/2 were increased in the MVEC since p38 phosphor-
ylation was not increased (data not shown).
There has been much discussion recently about the
putative presence of insulin and/or IGF-I receptors, or
chimeric receptors, in endothelial cells (39,40). We have
also found that the MVEC express IGF-1 receptors (data
not shown). Thus, we cannot exclude that signaling down-
stream the IGF-1 receptor is more important than that
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have suggested that IGF-1 is more important than insulin
for the generation of nitric oxide (NO) via the cognizant
receptor or via hybrid receptors in endothelial cells
(39,40). Nevertheless, our data show that the insulin
receptor was expressed and activated in the MVEC, and a
discussion about the relative quantity of each receptor
and/or the presence of hybrid receptors is beyond the
scope of this study.
It could be argued that subcutaneous MVEC are not
representative cells for studies of NO signaling. This may
to some extent be true because endothelial cells derived
from the microvasculature can in many ways differ from
macrovascular endothelial cells (e.g., Bovine Aorta and
Human Umbilical Vein). Indeed, tissue-speciﬁc expression
patterns in different MVEC suggest that they are distinct
cell types involved in the local regulation of their respec-
tive organs (41). Our observation that ERK1/2 is activated
in type 2 diabetes MVEC, like in the adipose cells (32),
highlights the potential of these cells to be involved in both
adipose tissue expansion through angiogenesis (42) as
well as adipose cell insulin sensitivity and action.
In conclusion, we have developed a procedure whereby
the subcutaneous MVEC can be isolated and cultured from
small tissue specimens in human subjects. Using this
technique, we ﬁnd that MVEC from type 2 diabetic patients
have a reduced IRS-1 protein expression and an impaired
insulin-stimulated PKB/Akt activation, whereas activation
of ERK1/2 was increased in the basal state. This activation
of ERK1/2 can be accounted for by the increased ET-1
levels in MVEC from type 2 diabetic subjects. These
observations support the concept of “selective” insulin
resistance as an underlying factor for a dysregulated
microvascular endothelium in type 2 diabetes. Further-
more, our results are consistent with the possibility that
the endothelial cells can cross talk with the parenchymal
cells and, thereby, be important modulators of insulin
sensitivity and action.
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